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ABSTRACT 23 
Biofilms are major causes of impairment of wound healing and patient morbidity. One of 24 
the most common and aggressive wound pathogens is Staphylococcus aureus, displaying a 25 
a large repertoire of virulence factors and commonly reduced susceptibility to antibiotics, 26 
such as the spread of methicillin-resistant S. aureus (MRSA). Bacteriophages are obligate 27 
parasites of bacteria. They multiply intracellularly and lyse their bacterial host releasing 28 
their progeny. We isolated a novel phage, DRA88 that has a broad host range amongst S. 29 
aureus. Morphologically the phage belongs to the Myoviridae family and comprises a large 30 
dsDNA genome of 141,907 bp. DRA88 was mixed with phage K to produce a high titre 31 
mixture that showed strong lytic activity against a wide range of S .  a u r e u s  isolates 32 
including representatives of the major international MRSA clones and coagulase-negative 33 
Staphylococcus. Its efficacy was assessed b o t h  i n  p l a n k t o n i c  c u l t u r e s  a n d  when 34 
treating established biofilms produced by three different biofilm producing S. aureus 35 
isolates. A significant reduction of biofilm biomass over 48 hours of treatment was 36 
recorded in all cases. The phage mixture may form the basis of an effective treatment 37 
for infectious caused by S. aureus biofilms. 38 
 39 
 40 
Key words: Staphylococcus aureus, bacteriophage therapy, biofilm, antibiotic resistant 41 
bacteria, MRSA, sequence analysis. 42 
 43 
 44 
 45 
 46 
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INTRODUCTION 47 
Staphylococcus aureus is an opportunistic human bacterial pathogen that primarily 48 
colonizes the anterior nares (1) but is frequently shed onto skin surfaces. When an 49 
opportunity occurs that facilitates its penetration of the skin surface, it is able to cause a 50 
broad spectrum of human diseases, from skin and soft-tissue infections to systemic 51 
infections such as pneumonia, meningitis and osteomyelitis (1, 2). Host invasion and immune 52 
evasion is possible due to a myriad of virulence factors, including toxins, adhesins and 53 
evasins (3). In addition, S. aureus infections often comprise strains with antibiotic resistance. 54 
Examples of these are penicillin and methicillin resistant S. aureus (MRSA) and isolates with 55 
decreased susceptibility to vancomycin (4).  56 
 57 
S. aureus is one of the most common gram-positive causes of wound infectious (5, 6). The 58 
wound environment is an ideal one for establishment of a bacterial infection as it contains 59 
large aggregations of necrotic tissue and accumulations of protein exudate (7). It is also 60 
observed that wound infections are strongly associated with the formation of biofilm 61 
communities (8). Once in a biofilm, bacterial cells experience greater protection against 62 
antibiotics and against elements of the host immune system, when compared to cells 63 
growing in a planktonic state (9). For example, the exopolysaccharide matrix blocks 64 
antibody penetration into biofilm (10) and phagocytes are unable to interact with bacterial 65 
cells (11). Biofilm structures are believed to be present in many acute wounds, but are very 66 
common in chronic wounds (12), and are a major factor delaying wound healing (12, 13). 67 
Moreover, many biofilms colonize implanted medical devices (14) greatly increasing 68 
patient morbidity and mortality and they are associated with larger health care costs (15). 69 
Chronic wounds affect 6.5 million patients in the United States and more than US$25 70 
billion are spent every year on treatment (16).  71 
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Current antibiotic options to successfully treat S. aureus are becoming scarce despite the 72 
development of some novel drugs (17), and there is a growing need for effective agents to 73 
combat infections (18). Bacteriophage therapy is a viable alternative / adjunct to antibiotics in 74 
treating bacterial infection (for review see (19)). Bacteriophages (phages) are viruses able to 75 
infect highly specifically and kill the bacterial species targeted, but not eukaryotic cells. The 76 
phage-encoded lysis proteins – endolysin and holin - cause the breakdown of the bacterial 77 
membrane (20) resulting in cell death and release of phage particles.  78 
 79 
Several studies have shown the potential of using phages to treat S. aureus infections (21–23) 80 
and it has been demonstrated that phages also have the ability to disrupt bacterial biofilms 81 
(24). Phages are increasingly recognized as serious candidates in the fight against antibiotic 82 
resistant bacteria in human therapeutics and as prophylaxis (25). Phages with strictly lytic 83 
life cycles, which result in a rapid killing of the target host and diminish the chances for 84 
bacteria to evolve towards phage resistance, are preferred for bacteriophage therapy use 85 
(26). It is also of value for the phage (or phage mixture) used to have a polyvalent nature, 86 
i.e. is able to infect a large set of strains within a species and may show improved 87 
applicability in situations where the etiological agent of an infectious disease has not been 88 
identified. 89 
 90 
Here we investigate the potential of using two lytic and polyvalent S. aureus phages:  K,  a  91 
well-documented  staphylococcal  phage  (27–29)  that attaches specifically to the cell wall 92 
teichoic acid (30) providing a wide host range; and a newly isolated phage, DRA88. Phage K 93 
was, previously, shown to be able to disrupt biofilms produced by S. aureus strains (28). 94 
Here, we characterized the antimicrobial activity of the phages alone and in combination in 95 
planktonic and biofilm systems. 96 
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MATERIALS AND METHODS 97 
Bacteria and Growth Conditions 98 
S. aureus strains (listed in Table 1) used in this study were from our collection of >5000 99 
clinical isolates and they were selected to be genetically diverse (by multilocus sequence 100 
typing (31)) and also to contain members of the major MRSA and MSSA clones present 101 
worldwide. Examples of eight coagulase-negative staphylococci: S. xylosus, S. sciuri subsp. 102 
sciuri, S. chromogenes, S. hyicus, S. arlettae, S. vitulinus, S. simulans and S. epidermidis 103 
were also included in this study. Bacteria from 5% (v/v) blood agar plates were grown at 37 104 
ºC with constant shaking (170 rpm) in Tryptic Soy Broth (TSB). Tryptic Soy Agar (TSA) 105 
and TSB-soft-agar containing 0.65% of bacteriological agar were used for bacteriophage 106 
propagation and plaque count assays. Note that media was supplemented with 1mM CaCl2 107 
and MgSO4 to improve phage adsorption (32). Bacterial aliquots were stocked at -80°C in 108 
broth containing 15% glycerol (v/v). 109 
 110 
Bacteriophage Isolation 111 
Bacteriophages were isolated from crude sewage (Thames Water PLC, Luton, UK). 112 
Bacterial enrichments with S. aureus isolates were performed to increase phage numbers as 113 
follows: 5 ml of actively growing S. aureus cells (from overnight liquid culture in TSB) 114 
and TSB supplemented with 1 mM MgSO4 and 1 mM CaCl2. The enrichment was 115 
incubated overnight at 37 ºC. A 10 ml aliquot was taken from the overnight culture and 1 M 116 
NaCl and 0.2% chloroform were added. The culture was then centrifuged (30 min, 3000 x 117 
g) to remove bacteria and the supernatant was filtered sterilized (0.22 µm pore size, 118 
Millipore filter).  This lysate (supernatant) was used to check the presence of lytic phages 119 
using the double layer method as described previously (33). Isolated single plaques were 120 
picked into SM buffer (5 M NaCl, 1M MgSO4, 1 M Tris–HCl [pH 7.5], gelatine solution 121 
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distilled water) and successive rounds of single plaque purification were carried out until 122 
purified plaques were obtained, reflected by single plaque morphology. Purified phages 123 
were stored in 50% glycerol (v/v) at -80 ºC for long term use. Short term stock 124 
preparations were maintained at 4 ºC. 125 
 126 
Bacteriophage Propagation 127 
Phage lysates were propagated on their respective bacterial hosts. Briefly, 100 µl of phage 128 
lysate and 100 µl of host growing culture were mixed and left for 5 min at room temperature. 129 
Afterwards 3 ml of soft-agar was added and poured onto TSA plates. The following day, 130 
after an overnight incubation at 37 ºC, plates displaying confluent lysis were selected and 3 131 
ml of SM buffer and 2% chloroform were added before incubating at 37 ºC for 4 h. High 132 
titre phage solution was removed from the plates, and centrifuged (8,000 x g, 10 min) to 133 
remove cell debris, then filter sterilized (pore size, 0.22 µm) and stored at 4 ºC. Both phages 134 
were propagated in the prophage-free isolate S. aureus RN4220 (40) to avoid potential 135 
contamination with mobilized phages (34).  136 
 137 
Sensitivity Assay 138 
To determine phage sensitivity of bacterial isolates spot tests were performed. Briefly, 3 ml 139 
of TSB-soft-agar was added to 100 µl of host growing culture and poured onto TSA. Plates 140 
were left to dry for 20 min at 37 ºC. The different phage lysates were standardized to a 141 
titre of 109 PFU/ml and 10 μl of each lysate were spotted onto the bacterial lawns. This 142 
assay was performed in triplicate. The plates were allowed to dry before incubating 143 
overnight at 37 ºC. The following day the sensitivity profiles of each of the bacterial strains 144 
were determined: if the bacterial lawn was lysed; slightly disrupted; or not disrupted, the 145 
bacterial isolate was labelled: sensitive; intermediate; or resistant to the phage infection. 146 
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Bacteriophage adsorption 147 
The experiment was carried out at 37 ºC under constant shaking (60 rpm) and a phage 148 
inoculum of MOI (Multiplicity Of Infection) = 0.01. The number of free phages was 149 
calculated from the PFU of chloroform-treated samples within 5 min after inoculation. The 150 
adsorption rate, assuming a first order kinetics was calculated in terms of the percentage of 151 
free phage loss by fitting phage decay curve (normalized as a percentage) to the rate 152 
equation: 153 
 154 
ln ሺ% phageሻ୲ ൌ ln ሺ% phageሻ୭ െ kԢt  (1) 155 
 156 
Where k’ is the pseudo 1st rate constant for free phage loss: 157 
 158 
kᇱ ൌ kሾbacteriaሿ  (2) 159 
 160 
From this, the percentage phage remaining at any time t can be easily calculated.  161 
 162 
One-step growth curve 163 
Phage growth cycle parameters  - the latent period (L), eclipse period (E) and burst size (B), 164 
were determined from the  dynamical  change  of  the  number  of  free  and  total  phages. 165 
Hence, one-step growth curves were measured as described by Pajunen et al. (35) with 166 
some modifications: 10 ml of a mid-exponential-phase culture were harvested by 167 
centrifugation (7,000x g, 10 min, 4ºC) and resuspended in 5 ml TSB to obtain OD600 of 1.0. 168 
To this suspension, 5 ml of phage solution were added to obtain a MOI (multiplicity of 169 
infection) of 0.001. Phages were allowed to adsorb for 5 min at room temperature. The 170 
mixture was than centrifuged as described above and the pellet was resuspended in 10 ml of 171 
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fresh TSB medium. Two samples were taken every 5 min over a period of 1 h at 37 ºC 172 
under constant shaking. The first samples were plated immediately without any treatment 173 
and the second set of samples was plated after treatment with 1 % (v/v) chloroform to release 174 
intracellular phages. 175 
 176 
Measurement of phage zeta potential and size 177 
The particle size and electrophoretic mobility of the phages was measured by Dynamic 178 
Light Scattering (DLS) using a Zetasizer Z/S (Malvern, UK) at 37 °C. Cuvettes filled with 179 
the sample were carefully inspected to avoid air bubbles.  Phages were diluted in dH2O to a 180 
final concentration of 108 PFU ml-1. Measurements were repeated at least three times. 181 
 182 
Electron Microscopy 183 
Phage particles in water were deposited on carbon coated copper grids and negatively stained 184 
with 1% uranyl acetate (pH 4). Visualization was performed using a transmission electron 185 
microscope (TEM) (JEOL JEM1200EXII, Bath, UK) operated at 120 kV.  186 
 187 
Phage DNA Extraction 188 
Concentrated phage preparations were obtained by a caesium chloride (CsCl) (Sigma, 189 
UK) gradient composed of three different solutions with densities of: 1.35, 1.50 and 1.7 g 190 
ml-1. They were prepared in a 36.5 ml ultracentrifuge tube (Beckman Coulter, Seton 191 
Scientific, UK). For the preparation of CsCl solution at a given density, ρ (g ml-1), the 192 
following equation was used to calculate the final CsCl concentration, c (g ml-1): c = 193 
0.0478ρ2  + 1.23ρ – 1.27 as well as the protocol described previously by Boulanger (36). 194 
After ultracentrifugation for 3 hours (75,600 g at 4 ºC) the phage band was collected and 195 
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dialysis was performed to remove CsCl residuals. Briefly, phage suspension was washed 196 
into dialysis cassettes (Slide-A-Lyser, Fisher, UK), which in turn were introduced in 500 197 
volumes of dialysis buffer (10 mM sodium phosphate, pH 7) for 30 min. After performing 198 
the process three times the concentrated and purified phage suspension was collected. 199 
Phenol/chloroform extraction was performed according to (37). 1.8 ml of phage lysates were 200 
treated with 18µl DNase I (1 mg ml-1) (Sigma Aldrich) and 8 µl RNase A (10 mg ml-1) 201 
(Sigma Aldrich) and incubated at 37 ºC for 60 min. Subsequently, 18 µl proteinase K (10 202 
mg ml-1) (Sigma Aldrich),  1% of sodium dodecyl sulphate (SDS) and 1 mM EDTA.Na2  203 
were added to the samples and these were incubated at 65 ºC for further 60 min. All 204 
protein material was eliminated by using phenol:chloroform:isoamyl alcohol (25:24:1) 205 
(Sigma Aldrich) and DNA extraction and precipitation was performed as described 206 
previously elsewhere (38). Nucleic acid concentration and quality was assessed with a 207 
Nanodrop spectrophotometer (Thermo Scientific, UK). 208 
 209 
DNA sequencing, analysis and assembly 210 
DNA sequencing libraries were prepared using the Nextera® XT DNA kit (Illumina, San 211 
Diego, USA) according to the manufacturer’s protocol. Individually tagged libraries were 212 
sequenced as a part of a flowcell as 2x250 base paired-end reads using the Illumina MiSeq 213 
platform (Illumina, San Diego, USA) at The Danish National High-Throughput DNA-214 
Sequencing Centre. Reads were analysed, trimmed and assembled using 6.5.1 CLC 215 
Genomic Workbench as described before by Kot et al. (39). Genes were predicted and 216 
annotated using RAST server (40). 217 
Planktonic cultures treated with phage mixture  218 
Planktonic cultures were performed in 96-well microtitre plates and their optical density 219 
was measured. In summary, a 1:100 dilution was prepared in the wells of the microplate by 220 
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adding 2 μl of an overnight culture to 198 μl of TSB. After 2 hours of incubation at 37 221 
ºC, the single or mixed phage at a MOI of 0.1 was added and the microplates were 222 
incubated for a further 24 hours. The incubation was followed on a plate reader (FLUOstar 223 
Omega, BMG LabTech, UK) where the growth curves were established at an optical 224 
density at 590 nm (OD590). This approach allows observation of the phage-bacteria 225 
interaction over time and also allows for monitoring of the appearance of resistant mutants 226 
for each phage lysate. 227 
 228 
Biofilm formation 229 
Biofilm assay was performed similarly to previously described methods ( 4 1 ) , but with 230 
some modifications in order to optimize the system. Biofilm formation was performed 231 
in 96-well polystyrene tissue culture microplates (Nunclon™ Delta Surface, Nunc, UK) to 232 
achieve an improved cell attachment.   TSB supplemented with 1% D-(+)-glucose (TSBg) 233 
and 1% NaCl (TSBg+NaCl) was used to perform this assay as this helps to improve 234 
biofilm formation (37, 38). An overnight culture was diluted to a titre of 108 cfu ml-1. 235 
Briefly, in the microplate wells a 1:100 dilution was performed by adding 2 μl of the 236 
bacterial suspension to 198 μl of TSBg+NaCl, making a starting inoculum of 106 cfu ml-1. 237 
200 μl of broth were added to a set of wells as a negative control. All wells were replicated 238 
three times. Afterwards, microplates were incubated at 37 ºC for 48 hours with no shaking 239 
for biofilm formation.  During the incubation time (~24 hours after incubation), 50 μl of 240 
fresh TSBg + NaCl was added to all control and test wells. Following incubation, medium 241 
was poured off and wells were carefully washed twice with sterile phosphate buffered 242 
saline (PBS) solution (Sigma Aldrich, UK) to remove any planktonic cells. Microplates were 243 
allowed to dry for 1 hour at 50 ºC. To determine total biofilm biomass microplate wells 244 
were stained with 0.1% Crystal Violet (CV). After staining the wells were washed twice 245 
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with PBS solution and dried. Biofilm formation was determined by visual comparison of the 246 
stained wells and photographed.  247 
 248 
Biofilm treatment with phage mixture  249 
Biofilm formation was carried out as described above. Once biofilms were established and 250 
washed once with PBS, 100 μl of phage mixture in PBS was added to a set of wells. Two 251 
different MOIs were set up for the single or mixed phage: 1 and 10. 100 μl of PBS were 252 
added both to the isolate positive and negative controls. All the experiments were performed 253 
three times. After static incubation  at  37 ºC  microplates  were washed and  stained,  as  254 
described  before,  at  pre-determined time-points. To perform optical density readings of the 255 
staining intensity, 100 μl of 95% ethanol (v/v) was added to each well and optical density at 256 
590 nm (OD590) was taken using a plate reader. 257 
 258 
Data analysis 259 
Comparisons between the different time points and the positive controls were made by 260 
performing a Student’s t-test and a p-value < 0.05 was considered statistically significant for 261 
all cases. All tests were performed with a confidence level of 95%. Spread of data at the 95% 262 
confidence interval (CI) was estimated using the Winpepi freeware statistical analysis 263 
program (42). 264 
 265 
Nucleotide sequence accession number 266 
The genome sequence of phage DRA88 has been deposited in the GenBank database 267 
under accession number KJ888149. 268 
 269 
 270 
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RESULTS 271 
Isolation and host range determination 272 
Several lytic phages were isolated in crude sewage samples from a water treatment facility 273 
and tested against the S. aureus bacterial collection listed in Table 1 in order to isolate phages 274 
with broad host ranges. One phage, DRA88, presented a host infectivity coverage of 60.0% 275 
(95% CI: 50% - 69%; 57 isolates out of 95 were susceptible) and so was selected for further 276 
studies. Phage K was also tested and showed host coverage of 64.2% (95% CI: 54% - 73%; 277 
61 isolates out of 95 were susceptible). These two phages were mixed in a phage mixture 278 
giving a total coverage of 73.7% (95% CI: 64% - 82%) of the S. aureus isolates assigned 279 
to 14 different MLST (Multilocus Sequence Typing) types. Infectivity of both phages was 280 
also tested on a group of coagulase-negative isolates, where DRA88 did not kill efficiently 281 
any of the isolates. Phage K showed also a weakly infectivity, however two of the isolates (S. 282 
simulans and S. hyicus) were sensitive (Table. 2).  283 
 284 
Phage Growth Characteristics 285 
The life cycle and adsorption affinity of phage DRA88 and phage K were assessed when 286 
growing in RN4220 S. aureus host at 37 °C. Firstly, one-step growth studies were 287 
performed to identify the different phases of a phage infection process. After infection, 288 
phage growth cycle parameters (L - latent, E - eclipse, and B – burst size) were determined 289 
(Fig. 1). In the system established, the eclipse and latent periods of DRA88 were, 15 290 
min and 25 min, respectively. DRA88 yielded a burst size of 76PFU and phage K of 125 291 
PFU per infected cell after 60 min. These phage life cycle values are in conformity with the 292 
values normally observed for T7 group phages (43). The adsorption efficiency of phages to 293 
the host was estimated with cells in the early logarithmic growth phase (Fig. 2). The 294 
adsorption rate (adsorption affinity) of the phages, when infecting actively growing S. 295 
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aureus RN4220, was measured. From equation (1), the rate constant for the adsorption (loss 296 
of free phage) for phage K and DRA88 were calculated (Fig. 2), k’ = 0.352 min-1 and k’ = 297 
0.252 min-1, respectively. Hence, although similar, after 5 minutes, 80.3% of phage K was 298 
adsorbed to the bacteria and 71.6% of DRA88. After 10 min, values for free viral particles 299 
were below 5% for both phages. 300 
 301 
Morphology of phage particles 302 
The isolated phage DRA88 was further characterized with regard to its morphology. 303 
Images of the phage DRA88 were developed using Transmission Electron Microscopy 304 
(TEM). The results revealed that phage DRA88 has, along with an icosahedral head of ~ 78 305 
nm in diameter, a long contractile tail of ~179 nm with tail fibers (Fig. 3A). Therefore it 306 
can be classified as belonging to  the  Myoviridae  family  (order  Caudoviridales), 307 
according  to  the  classification  system  of Ackermann (44). It was observed for phage 308 
DRA88 that besides single phage particles there were also various aggregates made 309 
through contact of their tail fibers (Fig. 3B). Phage K was also observed under TEM (Fig. 310 
S1), revealing a viral particle also belonging to the Myoviridae family (27). The zeta 311 
potential of phage DRA88 and phage K calculated from the electrophoretic mobility was 312 
-17 mV and -26.3 mV, respectively. The size measured was 122 nm for phage K, but 313 
according to the TEM micrographs and the literature this phage has an average size of 280 314 
nm total (45). This discrepancy could be due to contraction of tails, which was observed 315 
frequently, and can interfere with the measurement. Note that Dynamic Light Scattering 316 
(DLS) may show lower accuracy when measuring irregular shaped particles, such as tailed 317 
phages, where the size is not uniform in all dimensions. Regarding phage DRA88 we were 318 
not able to obtain an accurate size measurement and this can be related to the phenomena of 319 
aggregation observed under TEM. 320 
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Genomic characterization of DRA88 and comparison with phage K 321 
To gain a more ample understanding of the phage DRA88, its DNA was extracted and 322 
genome sequencing performed. Upon assembly and annotation it was found that phage 323 
DRA88 has a  large  double  stranded  DNA  genome  with  terminal  redundancy,  which  324 
suggests  that  phage DRA88 has a headful packaging system (46). The genome comprises 325 
141,907 bp and can be grouped into the class III of Staphylococcal phages (>125kbp) (47); 326 
204 putative coding regions and four tRNA genes were identified (Fig. 5 and Table 1 in 327 
Supplementary Data). The gene coding potential with 1.44 genes per kb, exhibits a high 328 
gene density. The majority of genes, 145 (71%), are found in the forward strand and 59 329 
(29%) in the opposite strand. tRNA genes are all located in the reverse strand of the 330 
genome. Regarding the GC% content it shows 30.4%, a lower percentage than the one 331 
found in the S. aureus host – 32.9%. The amino acid sequence was found to share strong 332 
similarities (>95%) with several other phages, such as JD007 and GH15 previously 333 
sequenced (48, 49). A comparison between phage DRA88 and phage K was performed 334 
using the BLAST algorithm (48). DRA88 genome seems to be organized into functional 335 
modules – cell lysis, DNA replication and structural elements – highly similar to the 336 
organization of phage K and other staphylococcal Myoviridae phages belonging to the 337 
Twort-like viruses (47, 50, 51). Between these modules we can find several putative coding 338 
regions that are not yet found in the NCBI database  or  have  no  attributed  function  339 
(phage  and  hypothetical  proteins).  These unknown functions represent 84.81% of the 340 
coding capacity.  Three potential coding regions (orf178, orf192 and orf195) did not have 341 
any identical match with phage genes in the NCBI database.  DRA88 lysin and DNA 342 
polymerase are not interrupted by introns (49), contrary to phage K, but similarly to phage 343 
GH15. At the end of the genome (between orf164 and orf182) there is a large coding 344 
region with u n i d en t i f i ed  functions inserted into the DRA88 genome that is not 345 
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observed in phage K. Also, DRA88 genome analysis did not reveal similarity to known 346 
virulent associated or toxin proteins. 347 
 348 
Bacteriophage mixture inhibits planktonic bacterial growth 349 
The efficacy of single DRA88 and phage K and their combination was assessed when treating 350 
bacterial cultures. Single phages and  the phage mixture (MOI = 0.1) were introduced in a 351 
bacterial culture already growing for two hours under planktonic conditions and let to 352 
incubate for further 22 hours (Fig. 5). Single phage treatment showed to be less 353 
successful in general than the phage mixture and this was cleared observed for S. aureus 354 
15981 isolate (Fig 5A).  For all three S. aureus bacterial cultures – 15981, MRSA252 and 355 
H325 – no cell growth was observed when the phage mixture was present compared to 356 
bacterial growth only. In fact, we observed efficient inhibition of the bacterial growth for 357 
15981 and H325. The same was not observed for MRSA 252, where we observed 358 
bacterial growth after 18 hours of treatment (time = 20 hours). 359 
 360 
Biofilm eradication 361 
Biofilms produced by the three S. aureus isolates were established in microtitre plates. 362 
All isolates were strong biofilm producers, however MRSA 252 followed by H325 isolates 363 
produced lower biofilm biomass and more fragile structure (when performing the 364 
mechanical washing steps the biofilm was more susceptible to disruption). The established 365 
biofilms were treated with single and mixed phage at MOI 10 and the biofilm was assessed 366 
(Figs 6 and 7). Measurement of biofilm density made using crystal violet / OD590 nm 367 
over 48 hours showed a clear reduction following phage inoculation compared with non-368 
treated controls (p = < 0.05). A decrease in biofilm biomass from the mixture compared 369 
with the single phages after 48 hours of treatment was seen in all cases, although not 370 
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significant it can been observed by eye (along with CV stained wells). Established biofilms 371 
were also treated with the phage mix at two different MOIs: 1 and 10,  and the biofilm was 372 
assessed at the time points: 0h, 2h, 4h, 24h and 48h (Fig 8). Unsurprisingly, phage mixtures 373 
with higher MOIs (10 compared with 1) gave a more rapid reduction in biofilm density, 374 
although both MOIs of 1 and 10 resulted in the same endpoint after 48 hours. For S. 375 
aureus 15981 biofilms treated with MOI 10, 4 hours after treatment, there was already 376 
more than 50% biofilm reduction (p-value < 0.05) and after 48 hours of treatment the 377 
biofilm biomass was almost completely disrupted (MOI 10, p-value = 4.82 x 10-3; MOI 1, 378 
p-value = 1.47 x 10-5) (Fig. 8A). Figure 8B shows that biofilms produced by MRSA 252 379 
were eliminated by more than 50% (MOI 10, p-value = 0.003; MOI 1, p-value = 0.012) after 380 
48 hours of phage treatment. At last, biofilms produced by H325 were not initially as strong 381 
as the other isolates. However we were able to observe a reduction of the biofilms as well 382 
over 48 hours for MOI 10 (p-value = 0.049). For MOI 1 a reduction of the biofilm 383 
structure was observed after 24 hours (p-value = 0.034). However such reduction was not 384 
observed after 48 hours.  385 
 386 
 387 
 388 
 389 
 390 
 391 
 392 
 393 
 394 
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DISCUSSION 395 
S. aureus biofilms in wounds and catheter sites present particular problems to patients , 396 
increasing morbidity, mortality and difficulty in delivering effective chemotherapy. For 397 
wound healing  to  occur,  treatment  of  the  biofilm  infection  is  essential  and  often  398 
requires selection of the correct antibiotic. The choice of appropriate chemotherapy is 399 
however made more difficult due to the increasing prevalence of antibiotic resistance. 400 
Hence, solutions are required to avoid treatment delay or ineffectiveness.  401 
 402 
The host range infectivity of DRA88 against a genetically diverse collection of S. aureus 403 
isolates was broad, showing that this is a polyvalent phage. Based on TEM analysis 404 
DRA88 belongs to the Myoviridae tailed- phage family. DRA88 adsorption occurred 405 
rapidly and at a similar rate to that observed for phage K, which is in accordance to several 406 
S. aureus Myoviridae infecting phages (52, 53). An interesting observation for phage 407 
DRA88 was the possible formation of phage aggregates. Phage aggregation is observed 408 
occasionally in nature (54, 55) and is dependent on pH, ionic strength and the composition 409 
of ions. Such phenomena could have been influenced by uranyl acetate (pH 4) used to 410 
stain the phages for TEM observation. However, DLS measurements (in d.H2O: ~pH 7) 411 
were unsuccessful and possibly due to several sizes found in the sample (singles and 412 
several aggregates), hence, we suspect that phage DRA88 is prone to form aggregates. When 413 
interacting with bacterial cells, aggregation could impede phage access to the cells and 414 
hence slow the rate of adsorption. Phage aggregation can be inhibited by optimization of 415 
growth media composition or stabilised in nano-emulsions resulting in phages that more 416 
efficiently attach to bacterial cells (56–58), consequently this could affect estimation of the 417 
PFU which then may not directly correspond with the number of infective particles (MOI).  418 
 419 
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At  the  genome  level,  DRA88 was revealed  to  be  a  large  dsDNA  phage,  usually a  420 
common characteristic of Myoviridae virus (50), carrying a high gene density and low 421 
GC%. It exhibits a high degree of relatedness to several other phages of the Twort-like 422 
group, including phage K. No virulence factors in the genome were identified, according to 423 
data available, suggesting that this phage could be safely used to treat S. aureus infections. 424 
The majority of putative coding regions of DRA88 genome do not have yet any function 425 
attributed yet, which is generally observed for the numerous phages being sequenced at the 426 
current time (59). Consequently, there is a crucial need for a more comprehensive 427 
investigation of phage genomes. Considering phage therapy as a therapeutic approach 428 
option, it is extremely important that we expand our knowledge regarding phage genes and 429 
proteins, and their respective functions and potentialities, as they can be involved in phage-430 
host interaction and even code for novel virulence determinants (60). 431 
 432 
The novel isolated phage was mixed into a phage mixture with phage K and as a result their 433 
lytic potential was increased (74 % of host coverage).  The use of a phage mixture is 434 
largely preferred over use of single phage as it results in a decreased rate of bacteria exhibiting 435 
resistance (61, 62). Bacterial broth cultures growing with phage mixtures showed an 436 
elimination of bacterial cells and suppression of resistant mutants. However, this was only 437 
observed for two strains; after 18 hours of growth, MRSA 252 was able to counteract the 438 
infectivity of the phage particles present in the culture, possibly due to the presence of phage 439 
receptor mutated clones present in the culture. This situation could be overcome or delayed by 440 
including more phage types to the therapeutic mixture, a task far easier (more rapid and likely 441 
to succeed) to undertake compared to the discovery of a new antibiotic. It has been 442 
demonstrated that phage therapy could be delivered in synchronization with another 443 
antibacterial therapy, such as antibiotics (63). Reducing the initial bacterial load could be 444 
19 
 
sufficient to bring the bacterial numbers under control so that the drug and also the action of 445 
the immune system can clear the infection (63–65) in an effective way.  446 
 447 
More than 60% of all infections are related to the formation of biofilms (12). Hence, it is 448 
important that biofilm model studies are investigated when testing a new antibacterial phage 449 
mixture. Some studies already suggest the significant potential of phages to reduce and/or 450 
eliminate biofilms. This is the case of phage K, where biofilms produced by S. aureus isolates 451 
showed a remarkable decrease in their biofilm biomass after addition of the phage (28, 41). 452 
Here, we showed that the phage mixture was able to reduce significantly the biofilm load on 453 
the polystyrene surface a microtitre plate. For isolate 15981 the eradication effect started 454 
readily after addition of the killing mixture and after 48 hours of treatment the biofilm was 455 
almost completely disrupted. Higher MOI showed a more rapid effect of biofilm reduction and 456 
a better prevention of biofilm regrowth was also observed for isolate H325. Comparing the 457 
effect of phage mixture on broth cultures to biofilm we observed a more positive effect on 458 
eliminating the bacterial load of broth cultures than that on biofilm, which is disrupted more 459 
slowly. This scenario was hypothesized to be due the metabolic state of the cells. In biofilms, 460 
cells can be in a low metabolic activity stage and phages cannot proliferate as efficiently as in 461 
active growing cells (41). To date, very few studies have been performed regarding phage 462 
mixture treatments, especially to treat S. aureus biofilms and in particular MRSA-caused ones.  463 
Kelly et al  (28)  have  already  shown  the  efficacy  of  a  phage  K  and derivatives mixture 464 
on the eradication of S. aureus biofilms produced by non-human clinical isolates. Here we go 465 
further by treating biofilms produced by prevalent human clinical isolates that also include 466 
MRSA types. This study suggests that the utilisation of a mixture of bacteriophage i.e. phage 467 
K  and DRA88 in this case, could provide a practical alternative to antibiotic / antimicrobial 468 
treatments for combating some S. aureus infections and in particular the devastating effects of 469 
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MRSA infections and biofilms related, such as burn-wound or catheter infection.  Even with 470 
the contribution of this study on the effectiveness of bacteriophage therapy to fight established 471 
bacterial infections, there is still a long way to go and several barriers to address.  The safety 472 
of phages and ethical and regulatory issues, for example, must be overcome in order to phages 473 
become an available alternative therapeutic (see review (66)). 474 
 475 
In summary, here we describe the isolation and characterization of a novel bacteriophage 476 
against pathogenic S. aureus bacteria. The phage, in combination with phage K, 477 
showed an improved range of infectivity of S. aureus isolates and a potent effect in 478 
biofilm dispersion making it a good candidate for further therapeutic development.  479 
 480 
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TABLE LEGENDS 673 
Table 1:  Sensitivity screening† of phage mixture against 95 S. aureus isolates. 674 
Further information regarding the isolate sequence type (ST) and origin are supplied. 675 
† Bacterial isolates were Susceptible – clear spot (S, light grey), Intermediate – turbid 676 
spot (I, medium grey) or Resistant – no disturbance of bacterial lawn (R, dark grey) to 677 
phage infection. 678 
Table 2: Sensitivity screening of phage mixture against coagulase-negative staphylococci 679 
isolates. † Bacterial isolates were Susceptible – clear spot (S, light grey), Intermediate – 680 
turbid spot (I, medium grey) or Resistant – no disturbance of bacterial lawn (R, dark grey) to 681 
phage infection. 682 
 683 
FIGURE LEGENDS 684 
Figure 1: Curve One-step growth of phage DRA88 (left) and phage K (right) in 685 
RN4220 S. aureus at 37 °C. Shown are the PFU per infected cell in untreated 686 
cultures (●) and in chloroform-treated cultures (○) at several time points over 60 687 
minutes. The phage growth parameters are indicated in the figure and correspond to: 688 
E - eclipse period; L - latent period and B - burst size. Each data point is the mean 689 
of three independent experiments and error bars indicate the mean ± standard 690 
deviation. 691 
Figure 2: Percentage of free (A) DRA88 and (B) Phage K phages after infection 692 
of actively growing RN4220 S. aureus at a MOI of 0.001 at several time points over 693 
10 minutes. Rate constants for loss of phage are 0.352 min-1 for Phage K and 0.252 694 
min-1 for DRA88. Each data point is the mean of three independent experiments and 695 
error bars indicate the mean ± standard deviation. 696 
Figure 3: Electron micrograph images of phage DRA88 negatively stained with 697 
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1% uranyl acetate, (A) showing the tail in a contracted position and (B) 698 
formation on phage particles aggregates. Scale bar is indicated. 699 
Figure 4: Comparative genomic analysis of phage DRA88 and phage K. Nucleotide 700 
sequences were compared using the Artemis Comparison Tool (ACT). Predicted ORFs 701 
are denoted by arrows, tRNAs are indicated (vertical blue dashed line) and genes encoding 702 
proteins with at least 69% amino acid identity between the two genomes are indicated by 703 
shaded regions. 704 
Figure 5: Dynamic of bacteria with single and phage mixture in liquid cultures over 24 705 
hours incubation at 37 °C. Absorbance readings at 590nm were taken in a microtitre plate 706 
reader. S. aureus isolates: A – 15981; B – MRSA 252; C – H325 growing with only SM 707 
buffer (○), with single DRA88 (▼), with single phage K ( ) and with the phage mixture in 708 
SM buffer (■) and also a negative control only SM buffer (●) are shown in the figure. Assays 709 
were performed four times and OD590 was expressed as the mean ± standard deviation. 710 
Figure 6 : Normalized biofilm biomass treated with single phage K, DRA88 and the phage 711 
mixture after 48 hours at MOI 10 (OD590 reading after CV staining). S. aureus isolates: 1 – 712 
15981; 2 – MRSA 252; 3 – H325. Mean values for the three strains treated with: phage K = 713 
0.63 (SD±0.10), 0.30 (SD±0.16), 0.27 (SD±0.06); DRA88 = 0.11 (SD±0.04), 0.18 714 
(SD±0.08), 0.29 (SD±0.03) phage mixture = 0.06 (SD±0.02), 0.15 (SD±0.02), 0.23 715 
(SD±0.02). Assays were performed three times and the mean ± standard deviation is 716 
indicated. Statistically significance of biofilm reduction was assessed by performing a 717 
Student’s t-test. p-values are indicated (* : <0.05). 718 
Figure 7: Visualization of wells stained with 0.1% of crystal violet after 48 hours of phage 719 
treatment at MOI 10. Shown are the biofilm wells treated with PBS, phage K, DRA88 and 720 
phage mixture at 0h (A) and (B) 48 hours after. Experiments were performed in triplicate. 721 
Figure 8: Normalized biofilm biomass treated with the phage mixture over 48 hours at two 722 
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different MOIs (OD590 reading after CV staining). S. aureus isolates: A – 15981; B – 723 
MRSA 252; C – H325. Assays were performed three times and the mean ± standard 724 
deviation is indicated. Statistically significance of biofilm reduction was assessed by 725 
performing a Student’s t-test. p-values are indicated (* : <0.05). 726 
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Table 1:  Sensitivity screening† of phage mixture against 95 S. aureus isolates. Further 748 
information regarding the isolate sequence type (ST) and origin are supplied. 749 
Isolates ST Country Phage K DRA88 Phage mixture 
WBG8343 1 Australia S I S 
MSSA H476 1 England S S S 
HT2001749 1 USA  S I S 
H148 3 UK  S S S 
CDC980193-USA800  5  USA S S S 
Mu3 5 Japan S R S 
963Small 5 USA S S S 
97.1948.S. 5 Scotland R R R 
C56 6 UK  S S S 
C2 7 UK  I I I 
CDC201114-USA300  8  USA S S S 
15981 8 Spain I S S 
HT20030203 8 USA I S S 
HT20030206 8 USA S I S 
C125 8 UK  I I I 
Fra97392 8 France  I R I 
EMRSA6 8 UK  I I I 
99st22111 8 -  S S S 
H169 9 UK S S S 
D316 11 UK I I I 
D329 12 England S S S 
H117 12 UK S S S 
H402 13  UK S S S 
C154 14 UK  S S S 
C357 15 UK S S S 
H291 18 UK S I S 
H42 20 UK S S S 
HO50960412 22 UK I S S 
H182 22 England S S S 
C720 22 England R S S 
C13 22 Eire  S S S 
C49 23 UK  S S S 
D279 25 UK  I I I 
Not116 27 UK  S S S 
H118 28 UK  S I S 
SwedenAO17934/97 30 Sweden  S I S 
Cuba4030 30 Cuba  I I I 
30 
 
C390 31  UK S S S 
H399 33  UK S S S 
C160 34  UK I I I 
Btn766 36 UK S S S 
MRSA 252 36 England S S S 
H325 36 UK S S S 
EMRSA16 36  UK S S S 
H137 38 UK I I I 
H137MRSA 38  UK S S S 
C253 40  UK I I I 
C427 42  UK S S S 
Fin76167 45  Finland S S S 
C316 49 UK S S S 
H417 50  UK S S S 
C3 51  UK S S S 
D49 53  UK S S S 
D98 54  UK I I I 
D318 57  UK S S S 
D535 59  UK I I I 
HT20050306  59  Australia I I I 
H40 60  UK S S S 
D473 69  UK I I I 
CDC201078-USA700  72  USA I I I 
HT20040991 80 Algeria S R S 
SwedN8890/99 80  Sweden I I I 
BK1563 88  USA I S S 
HT20020635 93 Australia S I S 
HT2001634 93  Australia I S S 
HT20020635 93 USA I S S 
Cuba4005 94  Cuba S S S 
D302 97  UK S S S 
Not38 101  UK S S S 
D472 109  UK S S S 
H560 121 UK S S S 
D139 145  UK I I I 
D22 182  UK I I I 
Can6428-011 188 Canada  S S S 
D470 207 UK  I I I 
98/10618 217 UK S S S 
CDC12 225 USA  S S S 
Germany131/98 228 Germany  S S S 
CDC16 231 USA  S S S 
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99.3759V 235 Scotland  S I S 
SwedenON408/99 246 Sweden  I I I 
KD121618 250 Switzerland S I S 
KD12943 257 UK  I I I 
Not271 264  UK I I I 
Not380 266  UK I S S 
Not98-53 280  UK I S I 
CAN6820-0616 289 Canada  I I I 
Fin62305 296  Finland  S I S 
Not266 301  UK  S S S 
Btn2164 312  UK S S S 
Btn2299 322  UK I I S 
Btn2289 322  UK S S S 
515/09 398 S S S 
Not161 517  UK S I S 
Not290 529  UK S S S 
† Bacterial isolates were Susceptible – clear spot (S, light grey), Intermediate – turbid spot (I, 750 
medium grey) or Resistant – no disturbance of bacterial lawn (R, dark grey) to phage 751 
infection. 752 
 753 
 754 
 755 
 756 
 757 
 758 
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 760 
 761 
 762 
 763 
Table 2: Sensitivity screening of phage mixture against coagulase-negative staphylococci 764 
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isolates. 765 
Species Isolates k DRA88 Phage Cocktail 
S. xylosus ATCC 29971 I I I 
S. sciuri subsp. sciuri ATCC 29062 I I I 
S. chromogenes CCM 3387 I I I 
S. hyicus      CCM 29368 S I S 
S. arlettae N910 254 I I I 
S. vitulinus ATCC 51145 I I I 
S. simulans    N920 197 S I S 
S. epidermidis ATCC 14990 I R I 
† Bacterial isolates were Susceptible – clear spot (S, light grey), Intermediate – turbid spot (I, 766 
medium grey) or Resistant – no disturbance of bacterial lawn (R, dark grey) to phage 767 
infection. 768 
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Figure 1: Curve One-step growth of phage DRA88 (left) and phage K (right) in RN4220 S. 
aureus at 37 °C. Shown are the PFU per infected cell in untreated cultures (●) and in 
chloroform-treated cultures (○) at several time points over 60 minutes. The phage growth 
parameters are indicated in the figure and correspond to: E - eclipse period; L - latent 
period and B - burst size. Each data point is the mean of three independent experiments 
and error bars indicate the mean ± standard deviation. 
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Figure 2: Percentage of free (A) DRA88 and (B) Phage K phages after infection of 
actively growing RN4220 S. aureus at a MOI of 0.001 at several time points over 10 
minutes. Rate constants for loss of phage are 0.352 min-1 for Phage K and 0.252 min-1 for 
DRA88. Each data point is the mean of three independent experiments and error bars 
indicate the mean ± standard deviation.  
 789 
 790 
 
Figure 3: Electron micrograph images of phage DRA88 negatively stained with 1%
uranyl acetate, (A) showing the tail in a contracted position and (B) formation on
phage particles aggregates. Scale bar (50 nm (A) and 100 nm (B) is indicated. 
 791 
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 793 
Figure 4: Comparative genomic analysis of phage DRA88 and phage K. Nucleotide 794 
sequences were compared using the Artemis Comparison Tool (ACT). Predicted ORFs 795 
are denoted by arrows, tRNAs are indicated (vertical blue dashed line) and genes encoding 796 
proteins with at least 69% amino acid identity between the two genomes are indicated by 797 
shaded regions.  798 
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Figure 5: Dynamic of bacteria with single and phage mixture in liquid cultures over 24
hours incubation at 37 °C. Absorbance readings at 590nm were taken in a microtitre plate 
reader. S. aureus isolates: A – 15981; B – MRSA 252; C – H325 growing with only SM 
buffer (○), with single DRA88 (▼), with single phage K ( ) and with the phage mixture in 
SM buffer (■) and also a negative control only SM buffer (●) are shown in the figure. Assays 
were performed four times and OD590 was expressed as the mean ± standard deviation. 
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Figure 6 : Normalized biofilm biomass treated with single phage K, DRA88 and the phage 
mixture after 48 hours at MOI 10 (OD590 reading after CV staining). S. aureus isolates: 1 – 
15981; 2 – MRSA 252; 3 – H325. Mean values for the three strains treated with: phage K = 
0.63 (SD±0.10), 0.30 (SD±0.16), 0.27 (SD±0.06); DRA88 = 0.11 (SD±0.04), 0.18 
(SD±0.08), 0.29 (SD±0.03) phage mixture = 0.06 (SD±0.02), 0.15 (SD±0.02), 0.23 
(SD±0.02). Assays were performed three times and the mean ± standard deviation is 
indicated. Statistically significance of biofilm reduction was assessed by performing a
Student’s t-test. p-values are indicated (* : <0.05). 
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Figure 7: Visualization of wells stained with 0.1% of crystal violet after 48 hours of phage 
treatment at MOI 10. Shown are the biofilm wells treated with PBS, phage K, DRA88 and 
phage mixture at 0h (A) and (B) 48 hours after. Experiments were performed in triplicate. 
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Figure 8: Normalized biofilm biomass treated with the phage mixture over 48 hours at two 
different MOIs (OD590 reading after CV staining). S. aureus isolates: A – 15981; B – 
MRSA 252; C – H325. Assays were performed three times and the mean ± standard 
deviation is indicated. Statistically significance of biofilm reduction was assessed by 
performing a Student’s t-test. p-values are indicated (* : <0.05). 
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